Marian L Burr
Overview
Explore the profile of Marian L Burr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
House I, Derrick E, Sek K, Chen A, Li J, Lai J, et al.
Cell Rep
. 2024 Feb;
43(2):113793.
PMID: 38324452
No abstract available.
2.
Ng J, Cai L, Girard L, Prall O, Rajan N, Khoo C, et al.
Clin Cancer Res
. 2024 Jan;
30(9):1846-1858.
PMID: 38180245
Purpose: The classification of small cell lung cancer (SCLC) into distinct molecular subtypes defined by ASCL1, NEUROD1, POU2F3, or YAP1 (SCLC-A, -N, -P, or -Y) expression, paves the way for...
3.
House I, Derrick E, Sek K, Chen A, Li J, Lai J, et al.
Cell Rep
. 2023 Aug;
42(8):113014.
PMID: 37605534
CXCL9 expression is a strong predictor of response to immune checkpoint blockade therapy. Accordingly, we sought to develop therapeutic strategies to enhance the expression of CXCL9 and augment antitumor immunity....
4.
Sparbier C, Gillespie A, Gomez J, Kumari N, Motazedian A, Chan K, et al.
Nat Cell Biol
. 2023 Jan;
25(2):258-272.
PMID: 36635503
Precise control of activating H3K4me3 and repressive H3K27me3 histone modifications at bivalent promoters is essential for normal development and frequently corrupted in cancer. By coupling a cell surface readout of...
5.
Chan K, Gomez J, Cardinez C, Kumari N, Sparbier C, Lam E, et al.
Cancer Cell
. 2022 Sep;
40(10):1190-1206.e9.
PMID: 36179686
There is increasing recognition of the prognostic significance of tumor cell major histocompatibility complex (MHC) class II expression in anti-cancer immunity. Relapse of acute myeloid leukemia (AML) following allogeneic stem...
6.
Rickard J, Burr M, Williams B, Murugasu A, Fellowes A, John T, et al.
Pathology
. 2022 Feb;
54(6):817-820.
PMID: 35177248
No abstract available.
7.
Garciaz S, Guirguis A, Muller S, Brown F, Chan Y, Motazedian A, et al.
Cancer Discov
. 2021 Dec;
12(3):774-791.
PMID: 34862195
Significance: Ironomycin couples targeting of cellular metabolism with cell death by reducing mitochondrial iron, resulting in the alteration of mitochondrial metabolism and the activation of BAX/BAK. Ironomycin induces MOMP through...
8.
Gilan O, Rioja I, Knezevic K, Bell M, Yeung M, Harker N, et al.
Science
. 2020 Mar;
368(6489):387-394.
PMID: 32193360
The two tandem bromodomains of the BET (bromodomain and extraterminal domain) proteins enable chromatin binding to facilitate transcription. Drugs that inhibit both bromodomains equally have shown efficacy in certain malignant...
9.
MacPherson L, Anokye J, Yeung M, Lam E, Chan Y, Weng C, et al.
Nature
. 2019 Dec;
577(7789):266-270.
PMID: 31827282
Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional dysregulation that results in a block in differentiation and increased malignant self-renewal. Various epigenetic therapies aimed at reversing these...
10.
Burr M, Sparbier C, Chan K, Chan Y, Kersbergen A, Lam E, et al.
Cancer Cell
. 2019 Oct;
36(4):385-401.e8.
PMID: 31564637
Loss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy resistance. A genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved function of polycomb repressive complex 2 (PRC2)...